KRAS and colonic neoplasm: In this study, we observed that miR-143 or miR-145 overexpression reduced cell proliferation and migration of mutant KRAS HCT116 colon cancer cells, and sensitized both mutant KRAS (HCT116 and SW480), as well as wild-type KRAS (SW48) cells to cetuximab.